Alternatively, more reliable methods to measure the levels of growth factors released by melanoma cells and stromal cells in patients’ tumors might be developed to investigate their potential role in defining patients with poor response to BRAF/MEK inhibitor therapy. The gene discussed is BRAF; the disease is melanoma.